Patents are good in that they tap into market economics to provide those functions, but they seem incomplete in cases like this.
1,196 karma · joined February 11, 2016
Patents are good in that they tap into market economics to provide those functions, but they seem incomplete in cases like this.
So they had a good drug candidate already but needed to tweak it because of the vagaries of IP law.
What a ridiculous situation. Has anyone devised a Shkreli-proof solution to this public policy issue?
So just start doing something. Choose one that appeals to you: help another person, create something, build friendships. You've spent enough time improving yourself through education, now it's time to focus outwards and give back.
Second, structure. Set some recurring reminders for starting. In the past I have used a dark trick: I asked a friend to be my "demotivator". His job was to knock me off track. If I didn't meet my personal commitment on a given day I would pay him $50. It worked extremely well.
On the other hand we have less exposure to the bacteria and parasites that live in the dirt and on animals. They trigger (and modulate) a different part of the immune system associated with allergies.
A better approach is to reward the portfolio with the highest Sharpe ratio, but even that is flawed because it ignores systemic risk and confuses historical volatility with actual risk.
Anyway, these games teach nothing about the essential habits of delaying gratification and living within your means. Those habits are far more likely to make you rich (and keep you rich) than any particular investment strategy.
Similarly, you are more likely to "hit the high notes" in research by concentrating effort in a few places. The alternative is lots of duplicated efforts that each don't quite achieve anything.
This applies especially to medical research where the barriers to getting meaningful clinical results are sky high.
Your PhD scholarship idea would see similar issues, including unforeseen bottlenecks which would starve out existing worthy research -- not just in this field but others too.
I think Ellison is right to be very particular about where he spends his money.
> However, getting regulatory approval for such a study, which would technically (as far as I know) be a first-in-man trial of HNK, might take a long time.
I don't understand this. We already know that when we give ketamine to patients they are exposed to HNK. Is there a real risk that it is more dangerous in isolation?
Even if caution is required in the first patients, why do we accept as normal that developing treatments like this should involve years of waiting for bureaucratic approval?
I parallelised the script, which is pretty easy in Python but involved refactoring into a more pure functional style. I abstracted out the algorithms and added in some persistent memoization as a bonus. It was clean and did what they needed, but... unfortunately was now completely unintelligible to the engineer who wrote it.
When I was asked back 6 months later to help again, they had reverted to using and modifying the old script. This time I kept the changes to the absolute minimum.
Of course the support organisation here (Google) should be well equipped to set up this kind of testing themselves and work with a customer to root cause the issue. In my experience though these issues are rarely taken seriously until there is no-one else left for support to blame.
jere, you do make a good point that there is more to it than just having free time and energy. e.g. There is also the "systemising" impulse often seen in high-functioning autistic individuals that seems suited to success in modern times.
http://esr.ibiblio.org/?p=7060
In short, the time and energy normally spent on social interaction instead is spent on other aspects of life.
I can imagine two situations as a researcher where constant criticism is damaging. (a) If you've built your self-image on being the best, and suddenly you're a small fish in a big pond, you're left with not much. (b) If you want to make a real difference but the culture of negativity/elitism holds you back, you end up frustrated.
But if you are actually making a difference then you can probably withstand any amount of sniping!
In the end though I do prefer working commercially, in a field where I can get intrinsic satisfaction from solving real-world problems instead of just having my name at the top of a list or being judged worthy by my peers.
(P.S. Not wanting to be too critical, but this page is almost impossible to read on mobile due to all of the pop-overs coming from different directions.)
It's not so much about memorising facts for recall (boring!) but training the mind for automatic action. Like offloading the grunt work to a subconscious co-processor and letting you focus on the bigger picture.
It all makes a lot of sense to me, but I have one thought. In many activities I find I need an initial period of tedious repetition before the fun part kicks in. Things like playing an instrument, learning a language, and some parts of mathematics. And nothing saps motivation at school more than being behind the class from the start and completely lost.
So is there a role to play for homework in pushing through the hard part at the beginning?
"Ridiculous": the whole point of the OP is that we don't have good predictive models for what treatments will be effective. We have hunches and theories but it is currently too costly to go through the whole process to test them all. One approach would be develop better models, but I'm suggesting another approach would be to reduce the cost of testing them in the real target.
"Inhumane": well that's the ethical question. Some countries compell vaccination because of the societal benefit. I'm not even proposing compulsion.
"Fundamentally ignorant": in the end medicine is needed to treat sick people, not healthy people. The OP makes the point that sometimes a biased, representative sample is better than an unbiased, unrepresentative sample.
Strangely enough, we already test vaccines and other drugs on healthy volunteers.
TGN1412 is a good example. This drug turned out to provoke the immune system in an extreme way. What if it had been tested first on cancer patients and, even with the life-threatening side effects, it worked as a cancer immunotherapy? Then we would be able to work on dosing or mitigation. Instead, the company folded, the research was abandoned and we'll probably never know.
And further, it's a cold calculation but instead of having healthy lives ruined you would have terminally ill patients die slightly sooner.
In my opinion we already know the best predictive model to use, but we choose not to use it. When Jenner developed the first vaccine back around 1800 he didn't use any petri dishes or mathematical models: he just found some nearby children and tested his theory directly.
Now you may find this ethically repulsive but from a consequentialist point of view it was the right thing to do at the time. This line of research saved hundreds of millions of lives.
I say we have gone too far in the other direction. The problem with failed costly clinical trials is not the failure per se but the cost: in money spent, time, reputation, commercial return, legal consequences, etc. And the hidden cost of how long the whole process takes even if successful.
Take the field of monoclonal antibodies. We now have almost off-the-shelf technology to develop drugs that specifically block certain biological mechanisms. But it still takes 10-15 expensive years to progress through different lab and animal models, then healthy humans, before clinical trials on actual patients.
Instead we should reduce the cost of human trials: have a network of terminally ill volunteers to test mabs at an early stage. Fail fast to move fast. Use the money saved to offer defined compensation when things go wrong.
The drugs that we really want to find are the ones with an obvious effect on real patients. This process would find those drugs much faster, and save lives overall.
Sometimes a high list price is combined with custom discounts to extract the most money from each customer. You see this more often when a market is closer to a monopoly, e.g. enterprise software with high lock-in.
In microeconomics you learn about the supply-demand curve. Normally there is a gap between the price the customer is willing to pay and the price the supplier is willing to accept. Depending on the market price, some of this gap is the consumer surplus, and some is the producer surplus (i.e. value gained by each party).
When a supplier has the power to set their price depending on the customer, they can capture all of the value under the demand curve and maximise profit at the expense of the customer.
A related strategy in retail is coupon discounts. Price-sensitive customers will take the time to use the coupon (when they otherwise would have not purchased), while others will pay the list price. This helps maximise the profit overall.
On top of this, one thing that surprised me was the difference in correction between red, green and blue light. The refractive index of the eye varies according to light frequency such that blue is focused approximately 2 dioptres more than red. If your myopic eyes are corrected for red at infinity, you won't be able to focus on any blue light further than 0.5m away! Not really a concern in the natural world but very noticeable in a server room full of blue LEDs or on a screen with blue text on black.
The difference in power between red and green is less but still useful enough for some vision tests. If you can focus on red traffic lights but green ones are blurry, this is why - consider a stronger power as long as it doesn't strain your near vision.